COAG
Hemab Therapeutics Holdings, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.21B
P/E Ratio
—
EPS
$-10.13
Beta
—
52W High
$36.61
52W Low
$18.00
50-Day MA
$26.71
200-Day MA
$26.71
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Hemab Therapeutics Holdings, Inc. Common Stock
Hemab Therapeutics Holdings, Inc. (Ticker: COAG) is a biopharmaceutical company focused on developing innovative therapies for rare bleeding disorders and hematologic conditions. With a strong pipeline grounded in its proprietary technology platform, Hemab aims to address significant unmet medical needs through advanced therapeutic approaches. The company's dedication to research and development, coupled with its strategic partnerships, positions it favorably to capitalize on market opportunities in the evolving landscape of hematology. Hemab's commitment to improving patient outcomes underscores its potential value as an investment in the biotechnology sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-69.81M |
| Operating Margin | 0.00% |
| Return on Equity | -47.00% |
| Return on Assets | -30.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-186.72 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $46.71M |
| Float | 456,130 |
| % Insiders | 10.78% |
| % Institutions | 59.91% |
More HEALTHCARE Stocks
Data last updated: 5/25/2026